Some of these results have implications outside hematopathology: in individuals other than those with Fanconi anemia, biomarkers of the FA/BRCA pathway can be used to predict the cisplatin or PARP1 (poly ADP ribose polymerase 1) inhibitor sensitivity of certain cancers. Here, PARP1 is linked to Fanconi anemia.